Furthermore, it has been reported that SGLT2 inhibitor (canagliflozin) inhibits glucose uptake, glycolysis and AKT/mTOR signaling activation in patients with PTC and increases activation of adenosine monophosphate-activated protein kinase (AMPK) and apoptosis in thyroid cancer cells, thereby reducing growth of thyroid cancer cells in vivo and in vitro [39]. This evidence concerns the gene MTOR and thyroid gland carcinoma.